BioSpace News Archive

Drug Development

Humacyte’s Engineered Blood Vessels in Final Push Toward BLA

Humacyte’s engineered blood vessels, human acellular vessels, are in a position to take tissue regeneration from a laboratory possibility to a commercial reality.

May 3, 2022
·
5 min read
·
Gail Dutton
Business

Dianthus Debuts with $100M and a Mission to Make Autoimmunity Less Inconvenient

Dianthus Therapeutics launched today with $100 million in Series A financing led by 5AM Ventures, Avidity Partners and Fidelity Research and Management. The company plans to tackle severe and rare autoimmune diseases by utilizing antibodies that target complements.

May 3, 2022
·
3 min read
·
Hayley Shasteen
Business

Teva Holds off Huntington’s Competitor, Resolves Opioid Cases

Teva announced that it had reached a deal with Lupin over Lupin’s Abbreviated New Drug Application (ANDA) for generic deutetrabenazine - an upcoming competitor to Hungtington’s drug Austedo.

May 3, 2022
·
3 min read
·
Mark Terry
Business

Denali/Sanofi ALS Candidate Hits Phase II as Awareness Month Begins

Denali Therapeutics, Inc. has announced that dosing has begun for participants of a Phase II clinical trial that intends to evaluate the potential of SAR443820 (DNL788) in patients with amyotrophic lateral sclerosis (ALS).

May 3, 2022
·
2 min read
·
Jazmine Colatriano M.S.
Policy

FDA Officials call COVID-19 the ‘New Normal’ in Op-Ed

Three long-time FDA officials, Dr. Peter Marks, Dr. Janet Woodcock and Dr. Robert Califf wrote an op-ed in JAMA describing the reality that COVID-19 represents “the new normal.”

May 3, 2022
·
3 min read
·
Mark Terry
Business

Genesis and Lilly Ink AI Collab Worth Up to $670M

Genesis Therapeutics and Eli Lilly have entered into a strategic collaboration to discover novel therapies utilizing Genesis’ AI platform.

May 3, 2022
·
2 min read
·
Hayley Shasteen
Drug Development

Fast Track Designation in Hand, Graphite Bio Guns for Definitive Sickle Cell Cure

GPH101 is an investigational next-generation gene-edited autologous hematopoietic stem cell (HSC) therapy.

May 3, 2022
·
2 min read
·
Hannah Chudleigh
Pfizer Leans Heavily on COVID-19 Vaccine, Treatments in Q1

Pfizer reported first-quarter revenues of $25.7 billion, a whopping 82% operational growth. This growth was largely driven by its COVID-19 vaccine developed with BioNTech and its antiviral drug, Paxlovid.

May 3, 2022
·
3 min read
·
Mark Terry
Policy

Embattled Researcher Sabatini Withdraws from Consideration for NYU Position

David Sabatini has withdrawn his name for consideration for a faculty post at New York University Langone Health.

May 3, 2022
·
2 min read
·
Alex Keown
Business

At ISCT This Week, Cell & Gene Therapy Grows Up

BioSpace sat down with Sven Kili, 2022 ISCT Annual Meeting co-chair, to preview the event, which will focus on 4 key subject areas including launch and commercialization of cell and gene therapies.

May 3, 2022
·
5 min read
·
Heather McKenzie